Alterations of mesenchymal stromal cells in cerebrospinal fluid: insights from transcriptomics and an ALS clinical trial.

Ashley A KrullDeborah O SetterTania F GendronSybil C L HrstkaMichael J PolzinJoseph HartAmel DudakovicNicolas N MadiganAllan B DietzAnthony J WindebankAndre J van WijnenNathan P Staff

Published in: Stem cell research & therapy (2021)

Overall, our results suggest that MSCs injected into the intrathecal space in ongoing clinical trials remain viable and may provide a therapeutic benefit to patients.

Keyphrases

clinical trial
end stage renal disease
cerebrospinal fluid
ejection fraction
newly diagnosed
chronic kidney disease
mesenchymal stem cells
peritoneal dialysis
bone marrow
phase ii
prognostic factors
randomized controlled trial
single cell
phase iii
patient reported outcomes
amyotrophic lateral sclerosis